<DOC>
	<DOCNO>NCT00054236</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Umbilical cord blood transplantation may able replace cell destroy chemotherapy . PURPOSE : Phase I trial study effectiveness combination chemotherapy follow umbilical cord blood transplantation treat patient hematologic cancer severe aplastic anemia .</brief_summary>
	<brief_title>Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation Treating Patients With Hematologic Cancer Severe Aplastic Anemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine incidence severity acute toxicity patient hematologic malignancy severe aplastic anemia treat non-myeloablative conditioning regimen follow umbilical cord blood transplantation . - Determine incidence severity acute chronic graft-versus-host-disease patient treated regimen . - Determine incidence relapse , disease-free survival , overall survival patient treat regimen . - Determine survival rate 100 day post-transplantation patient treated regimen . - Determine incidence regimen-related complication ( infection , hepatic veno-occlusive disease , interstitial pneumonitis ) patient treat regimen . - Determine incidence primary secondary graft failure patient treat regimen . - Determine rate kinetics donor-derived lymphoid , myeloid , neutrophil , RBC , platelet engraftment patient treat regimen . OUTLINE : Patients receive non-myeloablative conditioning regimen comprise fludarabine IV 30 minute day -8 -4 , cyclophosphamide IV 2 hour day -3 -2 , anti-thymocyte globulin ( ATG ) IV least 4 hour day -2 -1 . Patients unable tolerate ATG may receive methylprednisolone IV 1 hour day -3 -1 . Patients undergo multiple unit umbilical cord blood transplantation day 0-1 . Patients receive filgrastim ( G-CSF ) subcutaneously begin day 7 continue blood count recover . Patients follow monthly 6 month ; 9 , 12 , 14 , 16 , 18 , 24 month ; annually thereafter . PROJECTED ACCRUAL : A total 24 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow histologically confirm diagnosis : Acquired severe aplastic anemia Meets least 2 follow criterion : Granulocyte count le 500/mm^3 Platelet count le 20,000/mm^3 Absolute reticulocyte count le 20,000/mm^3 ( correction hematocrit ) Unresponsive OR recurrent disease prior treatment antithymocyte globulin and/or cyclosporine Acute myeloid leukemia ( AML ) , meet 1 follow criterion : Failed induction therapy In first complete remission ( CR ) follow highrisk feature : Stem cell biphenotype classification ( M0 ) Erythroleukemia ( M6 ) Acute megakaryocytic leukemia ( M7 ) Cytogenetic marker indicative poor prognosis ( 15 ; 17 ) translocation fail firstline induction therapy OR molecular evidence persistent disease ( 8 ; 21 ) inv ( 16 ) translocation fail firstline induction therapy In early relapse* In second subsequent remission Recurrent disease prior autologous stem cell transplantation ( SCT ) NOTE : *No refractory relapse Acute lymphoblastic leukemia , meet 1 follow criterion : In early relapse* In second subsequent remission In first CR follow highrisk feature : ( 4 ; 11 ) ( 9 ; 22 ) translocation Hyperleukocytosis ( initial WBC great 30,000/mm^3 ) Failed achieve CR day 28 standard induction therapy Recurrent disease prior autologous SCT NOTE : *No refractory relapse Chronic myelogenous leukemia Chronic accelerate phase fail medical management Blastic phase allow reinduction chemotherapy induce chronic phase Myelodysplastic syndrome meet 1 follow criterion : Refractory medical management Presence cytogenetic abnormality predictive transformation acute leukemia , include follow : = 5q = 7q Monosomy 7 trisomy 8 Evidence evolution AML ( e.g. , refractory anemia excess blast [ RAEB ] , RAEB transformation ) Chronic lymphocytic leukemia Refractory treatment include fludarabinebased therapy Recurrent disease prior autologous SCT Multiple myeloma Recurrent disease prior autologous SCT Beyond first CR fail induction therapy Disease sensitive pretransplantation cytoreduction Hodgkin 's lymphoma Beyond first CR fail induction therapy Disease sensitive pretransplantation cytoreduction NonHodgkin 's lymphoma ( NHL ) Recurrent disease prior autologous SCT Beyond first CR fail induction therapy Disease sensitive pretransplantation cytoreduction Mantle zone NHL allow induction therapy Myeloproliferative disorder Refractory medical management Allografting require unless grade 3 great myelofibrosis bone marrow biopsy No HLAmatched sibling donor available Ineligible myeloablative conditioning regimen due advanced age ( 55 ) , extensive prior therapy , and/or comorbidities If age 55 , must meet least 1 follow criterion : Received extensive prior therapy Organ toxicity infection preclude eligibility allogeneic transplantation full ablation condition Availability 25 umbilical cord blood unit least 4/6 HLA match No active CNS disease No primary grade 3 4 myelofibrosis PATIENT CHARACTERISTICS : Age Any age Performance status Karnofsky 70100 % ( patient 16 year age old ) Lansky 50100 % ( patient 16 year age ) Life expectancy At least 3 month Hematopoietic See Disease Characteristics Hepatic ALT/AST less 4 time normal Bilirubin le 2.0 mg/dL ( unless due hepatic infiltration primary malignancy ) Renal Creatinine clearance great 40 mL/min Cardiovascular Shortening fraction ejection fraction great 40 % normal value age echocardiogram radionuclide scan Pulmonary FVC FEV_1 great 60 % predict DLCO great 60 % predict ( adult patient ) Clearance pulmonologist require patient perform pulmonary function test Other Not pregnant nursing No uncontrolled active infection ( viral , bacterial , fungal ) HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics More 3 month since prior autologous stem cell transplantation Chemotherapy See Disease Characteristics At least 4 week since prior chemotherapy Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other Recovered prior therapy No concurrent investigational agent would preclude study participation increase risk patient Investigational diagnostic procedure allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>childhood acute erythroleukemia ( M6 )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>childhood acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>childhood acute megakaryocytic leukemia ( M7 )</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>childhood diffuse large cell lymphoma</keyword>
	<keyword>childhood immunoblastic large cell lymphoma</keyword>
	<keyword>Burkitt lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>